Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.

Diabetes Care
W Timothy GarveyOfri Mosenzon

Abstract

Most individuals with type 2 diabetes also have obesity, and treatment with some diabetes medications, including insulin, can cause further weight gain. No approved chronic weight management medications have been prospectively investigated in individuals with overweight or obesity and insulin-treated type 2 diabetes. The primary objective of this study was to assess the effect of liraglutide 3.0 mg versus placebo on weight loss in this population. Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs. Individuals were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198), combined with intensive behavioral therapy (IBT). At 56 weeks, mean weight change was -5.8% for liraglutide 3.0 mg versus -1.5% with placebo (estimated treatment difference -4.3% [95% CI -5.5; -3.2]; P < 0.0001). With liraglutide 3.0 mg, 51.8% of individuals achieved ≥5% weight loss versus 24.0% with placebo (odds ratio 3.41 [95% CI 2.19; 5.31]; P < 0.0001). Liraglutide 3.0 mg was associated with significantly greater reductio...Continue Reading

References

Apr 1, 1995·Annals of Internal Medicine·G A ColditzJ E Manson
Nov 5, 1999·JAMA : the Journal of the American Medical Association·A MustW H Dietz
May 28, 2005·Diabetes Care·F Xavier Pi-Sunyer
Mar 12, 2013·Expert Review of Clinical Pharmacology·Julia KenkreStephen Bloom
Sep 4, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J van CanW H M Saris
Aug 13, 2014·Diabetes Care·John B BuseUNKNOWN NN9068-3912 (DUAL-II) Trial Investigators
Jan 16, 2015·The Journal of Clinical Endocrinology and Metabolism·Caroline M ApovianUNKNOWN Endocrine Society
Aug 19, 2015·JAMA : the Journal of the American Medical Association·Melanie J DaviesRalph A DeFronzo
Mar 16, 2016·JAMA : the Journal of the American Medical Association
Sep 20, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Pauline M CamachoNelson B Watts
May 11, 2017·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·G A BrayUNKNOWN World Obesity Federation
Sep 30, 2017·The Lancet. Gastroenterology & Hepatology·Houssam HalawiMichael Camilleri
Apr 13, 2019·Clinical Trials : Journal of the Society for Clinical Trials·Devan V Mehrotra

❮ Previous
Next ❯

Citations

Jul 1, 2020·Journal of Endocrinological Investigation·F FerrariF Santini
Nov 29, 2020·The Journal of Clinical Endocrinology and Metabolism·Giovana F PiccoliFernando Gerchman
Jan 20, 2021·International Journal of Obesity : Journal of the International Association for the Study of Obesity·Sean WhartonJohn P H Wilding
Feb 2, 2021·Journal of Diabetes and Metabolic Disorders·Mandana HasanzadHamid Reza Aghaei Meybodi
Dec 17, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Thinzar Min, Stephen C Bain
Jun 4, 2021·Journal of Translational Medicine·Khaoula ErrafiiAbdelilah Arredouani
May 29, 2021·Bioorganic Chemistry·Ajay ManaithiyaImran A Khan
Jun 24, 2021·JAMA : the Journal of the American Medical Association·Susan Z Yanovski, Jack A Yanovski
Jul 8, 2021·Expert Review of Clinical Pharmacology·Dhiren Patel, April Smith
Oct 6, 2021·British Journal of Clinical Pharmacology·Rajmohan SeetharamanManjari Advani

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02963922

Software Mentioned

Lite
SAS
IWQOL

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.